ESR1 mutations are relatively prevalent in metastatic BC, with around 20–40% of patients treated with aromatase inhibitors (AI) exhibiting these mutations [50]; such mutations are thought to account for resistance in 50% of metastatic breast cancer (mBC) patients. This evidence concerns the gene CYP19A1 and breast cancer.